Loss of BCL9/9l was reported to block colonic tumorigenesis and mutations.51 Bcl9 and Pygo were found to synergize downstream of Apc to effect intestinal neoplasia in Apcmin/+ mouse models.53 BCL9/9L-β-catenin signaling is associated with poor outcome and affects stemness maintenance in colorectal CRC.54 Deregulation of BCL9 is an important contributing factor to tumor progression in CRC.55 But there is no reports about the role of BCL9 in immune-oncology yet. The gene discussed is BCL9; the disease is neoplasm.